Long-Term Upadacitinib Safety in Moderate-to-Severe Atopic Dermatitis up to 7 Years: An Integrated Analysis With Over 9600 Patient-Years of Exposure. J of Skin 2026, 10 (2), s727. https://doi.org/10.25251/evafb145.